Breaking News Instant updates and real-time market news.

FOLD

Amicus

$8.32

-0.58 (-6.52%)

17:17
11/28/16
11/28
17:17
11/28/16
17:17

Amicus to pursue more migalastat data as FDA rules out quick path

Amicus Therapeutics (FOLD) plunged in after-hours trading after ruling out accelerated approval for its migalastat product and confirming the need for additional data. AMICUS SAYS MORE DATA NEEDED: In a press release shortly after market close, Amicus detailed its "planned regulatory pathway to collect additional data to support full approval" of migalastat: "Following several collaborative discussions with the FDA, including the receipt of final written minutes from an in-person Type B meeting, the company plans to collect additional data on gastrointestinal symptoms in Fabry patients who have an amenable mutation. Key elements of the additional data generation... may include: Randomized, 12-month, placebo-controlled pivotal 'cross-over' study in treatment naive Fabry patients who have an amenable mutation and GI symptoms. Crossover study design provides sufficient powering with a small number of patients, ~35 patients planned. Primary endpoint to assess diarrhea based upon established FDA irritable bowel syndrome guidance." Amicus noted it is working with the FDA to finalize the clinical protocol and plans to initiate enrollment in 2017, with data expected in 2019. The company also disclosed that "during its review of the briefing document submitted and in discussions with Amicus, the FDA acknowledged that significant unmet medical need exists in Fabry disease. The agency also indicated that kidney globotriaosylceramide is currently not considered a basis for an accelerated approval under Subpart H." Weighing in on the news, CEO John Crowley stated, "While we believe that the totality of the data from our studies with migalastat support the submission of a new drug application today, we acknowledge the FDA's position that accelerated approval based on kidney GL-3 reduction is not currently an option... FDA has been flexible in allowing a crossover design and in our use of established GI endpoints to measure clinical benefit in Fabry patients. We are fully committed to the additional work necessary to move migalastat toward approval." PRICE ACTION: Shares of Amicus are down 27.76% to $6.01 in post-market trading.

FOLD Amicus
$8.32

-0.58 (-6.52%)

06/14/16
LEER
06/14/16
NO CHANGE
Target $19
LEER
Outperform
Protalix development encouraging for Amicus Galafold, says Leerink
Leerink analyst Joseph Schwartz is "incrementally encouraged" by the news that Protalix (PLX) reached an agreement with the FDA to advance its Fabry ERT into a pivotal trial, just before Amicus' (FOLD) meeting with the agency to discuss a regulatory path for its Galafold. Amicus was poised to emphasize non-renal data in the upcoming FDA meeting, but now the company has "another way to win" by using renal data, the analyst tells investors in a research note. Schwartz now assigns a 33% probability for Galafold. The analyst reiterates an Outperform rating on Amicus' stock and raised his price target on the shares to $19 from $17.
07/20/16
JPMS
07/20/16
NO CHANGE
Target $13
JPMS
Overweight
Amicus risk/reward 'compelling' at current levels, says JPMorgan
JPMorgan analyst Anupam Rama views the risk/reward for shares of Amicus Therapeutics at current levels as "compelling." After declining 39% year-to-date, Amicus is essentially only pricing in outside the U.S. Galafold sales in Fabry disease plus cash, Rama tells investors in a research note. Very little credit is being given to the company's U.S. migalastat, Zorblisa or the Pompe program, which all have events in the second half of 2016, the analyst contends. Rama thinks only one of the three need to hit for the stock to trade "materially higher," with upside ranging from 20%-100%-plus on a single success, and "meaningfully more upside" potential on multiple positive updates. Rama reiterates an Overweight rating on Amicus with a $13 price target.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

QCOM

Qualcomm

$57.22

0.08 (0.14%)

03:55
02/27/17
02/27
03:55
02/27/17
03:55
Conference/Events
Qualcomm to hold an investor session at Mobile World Congress 2017 »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 13

    Mar

03:05
02/27/17
02/27
03:05
02/27/17
03:05
General news
FX Update: The yen has seen a safe haven bid »

FX Update: The yen has…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

01:55
02/27/17
02/27
01:55
02/27/17
01:55
Conference/Events
Ericsson to hold a media and analyst briefing at Mobile World Congress 2017 »

Media & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 29

    Mar

SSNLF

Samsung

, T

AT&T

$42.36

0.41 (0.98%)

22:24
02/26/17
02/26
22:24
02/26/17
22:24
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

SSNLF

Samsung

T

AT&T

$42.36

0.41 (0.98%)

QCOM

Qualcomm

$57.22

0.08 (0.14%)

INTC

Intel

$36.53

0.35 (0.97%)

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

CMCSA

Comcast

$37.89

0.24 (0.64%)

CMCSK

Comcast

LGF.A

Lionsgate

$27.18

-0.08 (-0.29%)

LGF.B

Lionsgate

$25.16

-0.19 (-0.75%)

TV

Grupo Televisa

$26.44

0.69 (2.68%)

RIG

Transocean

$13.75

-0.56 (-3.91%)

GPN

Global Payments

$78.97

0.76 (0.97%)

AXTA

Axalta Coating

$29.38

-0.09 (-0.31%)

SNAP

Snap Inc.

HOG

Harley-Davidson

$56.56

-1.12 (-1.94%)

SAM

Boston Beer

$159.20

1.3 (0.82%)

STX

Seagate

$47.75

0.36 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 13

    Mar

  • 19

    Mar

  • 28

    Mar

  • 04

    Apr

  • 05

    Apr

  • 02

    Mar

NOK

Nokia

$5.14

-0.01 (-0.19%)

, VZ

Verizon

$50.60

0.29 (0.58%)

21:19
02/26/17
02/26
21:19
02/26/17
21:19
Hot Stocks
Nokia CEO: 'Noise' about carrier M&A to heat up in 2017 »

Speaking at a press event…

NOK

Nokia

$5.14

-0.01 (-0.19%)

VZ

Verizon

$50.60

0.29 (0.58%)

T

AT&T

$42.36

0.41 (0.98%)

TMUS

T-Mobile

$62.21

0.14 (0.23%)

S

Sprint

$8.94

-0.02 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 23

    May

SNE

Sony

$30.93

-0.31 (-0.99%)

20:43
02/26/17
02/26
20:43
02/26/17
20:43
Hot Stocks
Sony confirms 915,000 PlayStation VR global unit sales »

Sony Interactive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

  • 10

    Mar

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

20:38
02/26/17
02/26
20:38
02/26/17
20:38
Hot Stocks
Berkshire Hathaway says paid roughly $110.17 per share for Apple stake »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

AAPL

Apple

$136.66

0.13 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    Mar

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

20:31
02/26/17
02/26
20:31
02/26/17
20:31
Hot Stocks
Buffett: Will be 'ready to act' on share repurchase opportunities »

Writing in Berkshire…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

20:25
02/26/17
02/26
20:25
02/26/17
20:25
Hot Stocks
Samsung teases March 29 date for next Galaxy device »

Samsung has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

SNE

Sony

$30.93

-0.31 (-0.99%)

20:14
02/26/17
02/26
20:14
02/26/17
20:14
Periodicals
Sony sells 915,000 Playstation VR units in first four months, NYT says »

Speaking in a New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

  • 10

    Mar

AAPL

Apple

$136.66

0.13 (0.10%)

20:07
02/26/17
02/26
20:07
02/26/17
20:07
Hot Stocks
Al Gore sells 215,400 shares of Apple »

Apple board member and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    Mar

BBRY

BlackBerry

$7.08

-0.08 (-1.12%)

20:00
02/26/17
02/26
20:00
02/26/17
20:00
Hot Stocks
TCL Communication unveils 'BlackBerry KEYone' smartphone »

Smartphone manufacturer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$153.48

0.19 (0.12%)

, GD

General Dynamics

$189.63

1.33 (0.71%)

19:57
02/26/17
02/26
19:57
02/26/17
19:57
Periodicals
Trump to seek 'sharp' boost in defense spending, NYT says »

President Donald Trump…

RTN

Raytheon

$153.48

0.19 (0.12%)

GD

General Dynamics

$189.63

1.33 (0.71%)

LMT

Lockheed Martin

$266.00

1.15 (0.43%)

BA

Boeing

$177.44

0.58 (0.33%)

UTX

United Technologies

$112.46

0.37 (0.33%)

NOC

Northrop Grumman

$245.05

1.19 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMAX

IMAX

$32.75

1.6 (5.14%)

19:52
02/26/17
02/26
19:52
02/26/17
19:52
Hot Stocks
IMAX says China's Bona Film commits to 30 new IMAX theatres »

IMAX and IMAX China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 28

    Mar

  • 28

    Mar

F

Ford

$12.47

-0.09 (-0.72%)

, GM

General Motors

$36.90

-0.35 (-0.94%)

19:49
02/26/17
02/26
19:49
02/26/17
19:49
Periodicals
Chao says Trump administration reviewing autonomous car guidance, Reuters says »

Transportation Secretary…

F

Ford

$12.47

-0.09 (-0.72%)

GM

General Motors

$36.90

-0.35 (-0.94%)

TSLA

Tesla

$257.00

1.01 (0.39%)

GOOG

Alphabet

$828.64

-2.69 (-0.32%)

GOOGL

Alphabet Class A

$847.81

-3.19 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

19:35
02/26/17
02/26
19:35
02/26/17
19:35
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$75.88

-1 (-1.30%)

19:24
02/26/17
02/26
19:24
02/26/17
19:24
Periodicals
SoftBank poised to invest over $3B in WeWork, CNBC says »

SoftBank is nearing an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRPN

Groupon

$4.47

0.05 (1.13%)

19:22
02/26/17
02/26
19:22
02/26/17
19:22
Recommendations
Groupon analyst commentary  »

Piper believes Groupon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ALSN

Allison Transmission

$36.79

0.24 (0.66%)

, F

Ford

$12.47

-0.09 (-0.72%)

19:07
02/26/17
02/26
19:07
02/26/17
19:07
Downgrade
Allison Transmission, Ford rating change  »

Allison Transmission…

ALSN

Allison Transmission

$36.79

0.24 (0.66%)

F

Ford

$12.47

-0.09 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 11

    May

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

18:39
02/26/17
02/26
18:39
02/26/17
18:39
Hot Stocks
Berkshire Hathaway's Buffett: Expect normalized earning power to grow every year »

Writing in Berkshire…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

18:26
02/26/17
02/26
18:26
02/26/17
18:26
Hot Stocks
Deutsche Boerse sees European Commission merger decision by end of March »

Deutsche Boerse issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MESO

Mesoblast

$6.40

-0.14 (-2.14%)

18:23
02/26/17
02/26
18:23
02/26/17
18:23
Hot Stocks
Mesoblast outlines expected 2017 milestones »

Mesoblast stated that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Apr

LIOX

Lionbridge

16:58
02/26/17
02/26
16:58
02/26/17
16:58
Conference/Events
Lionbridge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$37.89

0.24 (0.64%)

, CMCSK

Comcast

16:54
02/26/17
02/26
16:54
02/26/17
16:54
Hot Stocks
Box Office Battle: Comedy horror 'Get Out' thrills in $31M opening »

Comcast's (CMCSA)…

CMCSA

Comcast

$37.89

0.24 (0.64%)

CMCSK

Comcast

TWX

Time Warner

$97.28

0.6225 (0.64%)

LGF.A

Lionsgate

$27.18

-0.08 (-0.29%)

LGF.B

Lionsgate

$25.16

-0.19 (-0.75%)

DIS

Disney

$110.32

0.59 (0.54%)

FOX

21st Century Fox

$30.23

0.23 (0.77%)

FOXA

21st Century Fox

$30.61

0.27 (0.89%)

VIA

Viacom

VIAB

Viacom

$43.89

0.03 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

WAT

Waters

$156.40

1.51 (0.97%)

16:38
02/26/17
02/26
16:38
02/26/17
16:38
Conference/Events
Waters to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 01

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.